Investigations by Leading Immune-Mediated Disease Research Organizations
Breakthrough T1D has partnered with the Lupus Research Alliance and the National Multiple Sclerosis Society to advance the understanding of…
Can a Psoriasis Drug Halt or Reverse Type 1 Diabetes?
Type 1 diabetes is one of the only major autoimmune diseases that doesn't have a disease-modifying therapy. A Breakthrough T1D clinical…
It’s Official: Teplizumab is Under Review by the FDA
The FDA regulatory review is now under way for teplizumab, to prevent or delay T1D in at-risk individuals. The target…
Discovery to Translation: Clinical Trial of a JAK Inhibitor in T1D
A Breakthrough T1D-funded clinical trial will test if a JAK inhibitor will preserve beta cell function in children and young…
What If You Could Halt Immune Cell Memory?
JDRF-funded researchers have discovered a protein on immune cells that, when it is disabled, could halt immune cell memory.
The Power of the Patient Voice: Breakthrough T1D Video
In the words of Colin Dayan, M.D., Ph.D., professor of clinical diabetes and metabolism at Cardiff University: “Type 1 diabetes…
Updates from the Teplizumab Trial: You’re Not Going to Believe the Results
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for…
Public and Private Organizations, All with the Same Goal: End T1D
In this time of great uncertainty, there is some exciting news out of Europe. Innodia, a partnership between public and…
Dr. Carla Greenbaum Talks about T1D TrialNet During the COVID-19 Pandemic
Carla Greenbaum, M.D., chair of TrialNet—an international Breakthrough T1D-supported network that is dedicated to finding cures for type 1 diabetes…
New Research Suggests that T1D Has Two Distinct Types
JDRF-funded researchers found that type 1 diabetes is comprised of two different subtypes, called endotypes, which are dependent upon the…
